AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion ...

AI has the potential to democratize information and enhance productivity - but at Snowflake Summit 2025, business leaders ...

See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Morningstar brands and products ...

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more. ... AstraZeneca’s plenary streak continues: ...